EMA: parent whenever possible [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2013-09-20 14:53 (4665 d 17:36 ago) – Posting: # 11531
Views: 32,487

Hi CR,

❝ So, do you recommend analysing both Spironolactone and the metabolites? If so, BE criteria (for MHRA) will be based on parent or both?


If you reliably can measure spironolactone, there is no need to measure any of its metabolites.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
307 visitors (0 registered, 307 guests [including 19 identified bots]).
Forum time: 08:29 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5